This article was reviewed by Darragh O’Carroll, MD. Oral vs. Injectable Semaglutide: Effectiveness & Side Effects Key ...

The 72-week multinational phase 3 ATTAIN-2 trial randomized 1613 participants with obesity or overweight (BMI ≥ 27.0) and T2D ...

Denmark-based Novo Nordisk, which makes Ozempic, Rybelsus and Wegovy; and Indianapolis-based Eli Lilly, which makes Zepbound, ...

The FDA has approved Rybelsus® to reduce the risk of MACE in adults with T2DM who are at high risk for these events.

Rybelsus is now FDA-approved for managing cardiovascular health. Doctors say oral GLP-1s may reduce heart attack and stroke ...

Lilly will offer its shot for $50 a month less than the current price through its direct-to-consumer platform called ...

Novo Nordisk NVO received FDA approval for a regulatory application seeking the label expansion of its oral GLP-1 drug, Rybelsus (semaglutide), to include cardiovascular (CV) risk reduction in adults ...

What Is Rybelsus, and Why Does It Matter? Rybelsus (semaglutide) is a once-daily pill used to help lower blood sugar in adults with type 2 diabetes (T2D). It belongs to a group of medicines called GLP ...

Denmark-based Novo Nordisk, which makes Ozempic, Rybelsus and Wegovy; and Indianapolis-based Eli Lilly, which makes Zepbound, ...

Novo Nordisk said on Wednesday it has accepted the U.S. Inflation Reduction Act (IRA)'s maximum fair price for its diabetes ...

Novo Nordisk and Eli Lilly become latest drug companies to bend knee to Trump’s ‘most-favored nation’ pricing plan ...

Please provide your email address to receive an email when new articles are posted on . The FDA approved oral semaglutide for primary and secondary prevention of CV events in high-risk adults with ...